Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Fairhurst, NY
David Fairhurst, Congers, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20100034863 | Delivery Devices Containing Encapsulated and/or Particle-Bound Active Pharmaceutical Ingredients - Delivery devices of a degradable or nondegradable biocompatible matrix with one or more encapsulated active pharmaceutical ingredients or one or more particle-bound active pharmaceutical ingredients dispersed in the matrix are provided. Also provided are methods for delivering an active pharmaceutical ingredient to a subject with these delivery devices. Modified vaginal rings are also provided as well as surface coatings for delivery devices which minimize bio-interaction of the coated delivery devices. | 02-11-2010 |
| 20100062071 | Particle Formulations and Uses Thereof - Aqueous dispersions of chemically and physically stable particles for use in delivery of active pharmaceutical ingredients and processes for their production and use to enhance a biological response to an active pharmaceutical ingredient and prophylactically or therapeutically treat a subject are provided. Vaccines, wherein the active pharmaceutical ingredient is a solution of subunit vaccine antigen mixed with a colloidal dispersion of electrically charged particles and use of such vaccines in immunization are also provided. | 03-11-2010 |
| 20100086608 | Methods and Devices for Detecting Binding Events via Zeta-Potential and Pharmacologically Active Compounds and Delivery Systems Identified Thereby - Methods, devices and arrays for measuring a change in zeta-potential of a surface indicative of a binding event are provided. Pharmacologically active compounds and delivery systems for active pharmaceutical ingredients determined to be pharmacologically active or optimized for pharmacological activity or determined to be useful for delivery of the active pharmaceutical ingredient to a target via measurement of a change in zeta-potential of the compound, ingredient or delivery system are also provided. | 04-08-2010 |
Jeanette L. Fairhurst, White Plains, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20090074793 | High Affinity Human Antibodies to Human IL-4 Receptor - An isolated human antibody or antibody fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4Rα) with high affinity (K | 03-19-2009 |
| 20100021476 | High Affinity Human Antibodies to Human IL-4 Receptor - The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor. | 01-28-2010 |
| 20100034833 | HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN IL-18 RECEPTOR - An isolated antibody or antibody fragment that binds human interleukin-18 receptor alpha (hIL-18Rα), comprising a light chain variable region (LCVR) selected from the group consisting of SEQ ID NO: 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 61, 65, 69, 73, 77, and 81 and/or a heavy chain variable region (HCVR) selected from the group consisting of SEQ ID NO: 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, 51, 55, 59, 63, 67, 71, 75, and 79, or a fragment or sequence modified by an amino acid substitution, deletion or addition thereof. | 02-11-2010 |
| 20100047254 | High Affinity Human Antibodies to Human IL-4 Receptor - The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor. | 02-25-2010 |
| 20100291107 | HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN IL-4 RECEPTOR - The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor. | 11-18-2010 |
| 20100316627 | Human antibodies to human IL-6 receptor - A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a K | 12-16-2010 |
| 20100316636 | Method of Treating Rheumatoid Arthritis with an IL-6R Antibody - The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof. | 12-16-2010 |